Article
-
Article
To Spend Less on Healthcare, Invest in More Medicines
04.05.2022
Read John Stanford and JF Formela's op-ed on how we can lower health costs by spending more on drugs.
-
Article
CMS’s Devastating Blow to Seniors
02.09.2022
Read Incubate Advisory Council member Gaurav Gupta's op-ed on the CMS's decision to cover Alzheimer's drugs.
-
Article
Investors Say Drug-Pricing Measure May Shift Incentives for Biotech Venture Funding
12.02.2021
A drug-pricing bill the House passed in November could affect which life-sciences startups venture-capital investors are likely to back.
-
Article
House passage of Build Back Better gets mixed reaction
11.22.2021
As investors in biotechnology and pharmaceuticals, we're alarmed by the potential consequences of the drug-pricing measure included in the Build Back Better Act, which just passed the House.
-
Article
Regeneron, Janssen Drugs Fit Profile Targeted in Spending Bill
11.10.2021
Plan would negotiate prices of expensive older pharmaceuticals Moderate Democrats sought compromise to preserve innovation
-
Article
Drug pricing bill’s unintended consequences will distort drug development
11.09.2021
The ultimate victims of all the unintended consequences of the current proposal will be all of us as future patients.
-
Article
Leading Venture Capital Group Concerned with Prescription Drug Deal
11.04.2021
Investors in biotechnology and pharmaceuticals aere concerned about the potential consequences of the new drug-pricing legislation before Congress in the Build Back Better Act.
-
Article
Cost of Care: Rare diseases expose need to revamp US drug pricing policy
10.20.2021
Developing more effective treatments for patients with no other options while also keeping costs down will require a balancing act with no clear solution
-
Article
Democrats’ Drug Price Controls Threaten Biotech Research, Patients
09.21.2021
Biotech investors sounded alarms at the National Press Club last week about what they would mean. They said the price-control scheme would dry up investor interest in the biotech sector.
-
Article
VC Daily: Venture Capitalists Push Back Against Drug-Pricing Bill
09.16.2021
If price controls are enacted on drugs, investment will no longer flow to innovative new biotech treatments
-
Article
Venture firms warn R&D funding for new drugs will ‘drop off a cliff’ if Dem bill approved
09.16.2021
Democrats move forward with giving Medicare the power to negotiate drug prices for certain drugs and extend those prices to commercial plans.
-
Article
Cost of Care: Biotech VCs fret over ‘thumb on the scale’ Medicare reform plans
09.15.2021
For venture capitalists investing in companies at the earliest stages of scientific discovery and drug development, the ramifications of pricing control could change the landscape in ways that vastly undermine future funding decisions